Thase M E, Howland R H, Friedman E S
Department of Psychiatry, University of Pittsburgh School of Medicine, and the Western Psychiatric Institute and Clinic, PA 15213, USA.
J Clin Psychiatry. 1998;59 Suppl 5:5-12; discussion 13-5.
This paper provides an overview of antidepressant nonresponse and the role of augmentation strategies in the management of treatment-resistant depression. When effective, the more widely used augmentation strategies, including lithium salts, thyroid hormones, pindolol, buspirone, and psychostimulants, share two important advantages when compared with "switching" strategies: avoidance of ill effects associated with discontinuing the initial antidepressant and rapidity of onset of action. Ideally, advances in the understanding of the neurobiology of mood disorders and mechanisms of antidepressant response will permit a more efficient and specific matching between patient, initial antidepressant, and subsequent strategy for enhancing response to treatment.
本文概述了抗抑郁药无反应情况以及增效策略在难治性抑郁症治疗中的作用。当有效的增效策略(包括锂盐、甲状腺激素、吲哚洛尔、丁螺环酮和精神振奋药)被更广泛应用时,与“换药”策略相比,它们具有两个重要优势:避免了停用初始抗抑郁药相关的不良影响以及起效迅速。理想情况下,对情绪障碍神经生物学和抗抑郁反应机制认识的进展将使患者、初始抗抑郁药以及后续增强治疗反应策略之间能有更高效且特定的匹配。